VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.67 USD
+0.02 (0.75%)
Updated May 10, 2024 03:59 PM ET
After-Market: $2.66 -0.01 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/12/24 |
---|---|
Current Quarter | -0.25 |
EPS Last Quarter | -0.15 |
Last EPS Surprise | 37.50% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -1.00 |
Next Year | -0.96 |
EPS (TTM) | -5.28 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 0.11M | 0.11M | 0.40M | NA |
# of Estimates | 1 | 1 | 1 | NA |
High Estimate | 0.11M | 0.11M | 0.40M | NA |
Low Estimate | 0.11M | 0.11M | 0.40M | NA |
Year ago Sales | 0.14M | 0.11M | 0.42M | 0.40M |
Year over Year Growth Est. | -21.43% | 0.00% | -5.66% | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.25 | -0.25 | -1.00 | -0.96 |
# of Estimates | 1 | 1 | 1 | 1 |
Most Recent Consensus | -0.24 | -0.25 | -1.00 | -0.96 |
High Estimate | -0.25 | -0.25 | -1.00 | -0.96 |
Low Estimate | -0.25 | -0.25 | -1.00 | -0.96 |
Year ago EPS | -3.08 | -1.85 | -2.72 | -1.00 |
Year over Year Growth Est. | 91.88% | 86.49% | 63.24% | 4.00% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.25 | -0.25 | -1.00 | -0.96 |
7 Days Ago | -0.25 | -0.25 | -1.00 | -0.96 |
30 Days Ago | -0.25 | -0.25 | -1.00 | -0.96 |
60 Days Ago | -0.25 | -0.25 | -1.00 | -0.96 |
90 Days Ago | NA | NA | -2.10 | -2.19 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.25 | -0.25 | -1.00 | -0.96 |
Zacks Consensus Estimate | -0.25 | -0.25 | -1.00 | -0.96 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.15 | -0.20 | -1.85 | -3.08 | NA |
Estimate | -0.24 | -0.50 | -0.76 | -1.99 | NA |
Difference | 0.09 | 0.30 | -1.09 | -1.09 | -0.45 |
Surprise | 37.50% | 60.00% | -143.42% | -54.77% | -25.17% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more